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had high regional prevalence of AF in 2011. Geographic variation in high risk 
areas can help identify important geographically connected prognostic factors, 
aid in targeted intervention strategies, and generate hypotheses regarding 
underlying causes of AF in the United States and associated territories.  
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DISEASE BURDEN OF ATRIAL FIBRILLATION, COLOMBIA 2000-2009  
Romero M, Chavez D 
Fundacion Salutia, Bogota, Colombia  
OBJECTIVES: To estimate the disease burden of atrial fibrillation and to describe 
its impact on Colombian population health METHODS: We calculated Disability 
Adjusted Life Year (DALYs) for atrial fibrillation, by adding years of life lost due 
to premature mortality (YLL) plus years lived with disability (YLD). For 
calculating YLL it were consulted both death registration and abridged-life tables 
at national statistic agency DANE for 2000-2009. For calculating YLD it were 
consulted individual records of service providers for 2009-2010. It were also 
consulted the map of weighted disability from the Global Burden of Disease 
study. For data processing we used a template developed in Microsoft Excel® 
according to the method described by WHO in October 2001 and taking into 
account the parameters and formulas that have been described by Murray and 
Lopez (1996) and Mathers et al (2001). RESULTS: In 2000, 2004 and 2009 it was lost 
due to atrial fibrillation 12,138; 13,188 and 15,327 DALYs in the Colombian 
population with a ratio of 0.30, 0.31 and 0.34 DALY per thousand people 
respectively. The relative weight of DALYs was given by the disability component 
(91.46%). Men accounted for an average of 58% of estimated DALYs; and the most 
affected age was that of 70-79 years old CONCLUSIONS: The estimated DALYs 
show that atrial fibrillation is a disease highly disabling in the Colombian 
population during the study period, given the predominance of the component 
of years lived with disability (YLD).  
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STUDY OF DAY-TIME RHYTHM OF STROKE ONSET IN CHINESE  
POPULATION  
Wang YL1, Xu J1, Xie XP2, Wang YJ1 
1Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China, 2Pfizer China, 
Beijing, China  
OBJECTIVES: Most of the studies of time distribution of stroke onset in the 
Chinese population have a limited number of cases, and national-level data 
analysis is rare. In this study, circadian rhythm of stroke onset in the Chinese 
patients was observed on the basis of the China National Stroke Registry (CNSR) 
data. METHODS: Continuous prospective registration of new-onset acute 
cerebrovascular events within 14 days was conducted based on nationwide 
multi-center, continuity, prospective stroke registry data, and 1-year follow-up 
was performed to analyze the differences in time pattern and prognosis of the 
onset of strokes of different etiological subtypes and clinical sub-types. 
RESULTS: A total of 9588 people entered the statistical description after cases 
with absence of time of onset and wake-up stroke were excluded from all of the 
stroke cases (including IS, ICH, SAH, TIA). The period from 7:00 to 12:00 appeared 
to be a significant peak for stroke onset. According to different stroke sub-types, 
onset peak in the morning was more prominent in 5796 cases of IS and 399 cases 
of TIA; 2,666 cases of ICH and 399 cases of SAH presented two onset peaks from 
7:00 to 12:00 and from 17:00 to 19:00. The cases showed the same trend 
irrespective of initial onset or recurrence and with or without hypertension. 
Through logistic regression model analysis, gender, age, history of Arial 
Fibrillation, smoking history and other factors were related to the time of stroke 
onset to a certain extent. CONCLUSIONS: The time of stroke onset in Chinese 
patients is generally in the morning. The trend of IS onset is particularly evident. 
Therefore, paying more attention to morning care and blood pressure control 
during morning will be important.  
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HOSPITALIZATION AND MORTALITY IN MEDICARE HEART FAILURE PATIENTS  
Hunt PR1, Veath BK2, Tsintzos S3, Burton ML3, Mollenkopf SA3 
1United BioSource Corporation, Inc., Lexington, MA, USA, 2Medtronic International Ltd., Mounds 
View, MN, USA, 3Medtronic, Inc., Mounds View, MN, USA  
OBJECTIVES: Heart Failure (HF) is a leading cause of morbidity and mortality in 
the US, and hospitalization for HF appears to be steadily increasing. We sought 
to identify HF patients and understand the patterns of care for HF in a real-world 
setting through analysis of a retrospective observational database. METHODS: 
The study population consisted of patients in the Medicare 5% database with a 
primary inpatient diagnosis of HF (ICD-9-CM 428.0, 428.9, 428.20-23, 428.30–33, 
428.40–43) during CY2005–2008. Patients were followed for up to 33 months (6 
months baseline, 3 month index, 24 months follow-up. To exclude prevalent 
cases, patients were required to have no diagnoses of HF in the baseline period. 
The quarter of the initial HF inpatient diagnosis was designated the “index 
quarter”. Each patient was followed for up to two years (8 quarters) after the 
index quarter, or until death or end of enrolment. Frequency of service use based 
on care setting; diagnosis was determined for the “index quarter” and follow-up 
period. RESULTS: A total of 43,819 patients with new primary HF inpatient 
claims were identified in the four year study period. Within the 27 month follow-
up (includes “index”), the identified HF patients had 140,802 inpatient 
hospitalizations (3.2 per patient), of which 66,334 (1.5 per patient) had a primary 
HF diagnosis (includes index HF hospitalization). 23% of identified HF patients 
had one or more HF hospitalizations within two years after the “index”. 
Annualized mortality was 26.4%/year over the first five quarters (includes 
“index”) and 14%/year over quarters 5 through 8. Total mortality was 42.4% 
(18,562/43,819). CONCLUSIONS: Extrapolation of these results suggest that new 
inpatient HF admissions may account for 145,000 HF inpatient hospitalizations. 
HF Mortality after the “index” admission was >40%. Our results underline HF as a 
major clinical and economic burden in the United States.  
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COMMON PREGNANCY SYMPTOMS INCREASE THE RISK OF CARDIOVASCULAR 
DISEASE  
Zulkifly H1, Dingle KD2, Clavarino A2 
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OBJECTIVES: To identify the long term effects of common symptoms of 
pregnancy and whether these increase the risk of cardiovascular disease or 
symptoms associated with it in women at 21 years after pregnancy. METHODS: 
Data used were from the Mater University Study of Pregnancy (MUSP), a 
community- based prospective birth cohort study begun in Brisbane, Australia, 
in 1983. Chi square test and logistic regression analyses were conducted. 
RESULTS: Data were available for 3692 women. In cross tabulations, morning 
sickness, heartburn and backache show positive association (p<0.05) with 
different cardiovascular outcomes. However, in the multivariate models, only 
those experiencing heartburn (adjusted OR 1.3, 95% CI 1.0-1.7) during pregnancy 
were at greater risk of having hypertension 21 years post partum. Women 
experiencing morning sickness (adjusted OR 1.2, 95% CI 0.8-2.0) and backache 
(adjusted OR 1.1, 95% CI 0.6-1.7) were not considered to be at risk for future heart 
disease. CONCLUSIONS: As a whole, our study suggests that most common 
symptoms of pregnancy are not associated with an increased risk of 
cardiovascular disease or with hypertension in the long term.  
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WARFARIN DOSE ADJUSTMENTS DUE TO DRUG-DRUG INTERACTION WITH 
DRONEDARONE: A CASE-CONTROL STUDY  
Yeh JY1, Parker M2 
1Long Island University, Brooklyn, NY, USA, 2Cleveland Clinic, Cleveland, OH, USA  
OBJECTIVES: Dronedarone and warfarin are commonly used concurrently in the 
treatment and prevention of stroke caused by atrial fibrillation. Previous data 
from clinical trials suggest a drug-drug interaction between warfarin and 
dronedarone should exist. However, the dosing strategy of warfarin related to 
dronedarone remained unclear in real-world settings. This observational study 
aimed to assess the effect of starting dronedarone in patients with stable INRs in 
daily practice. METHODS: A case-control design was employed. Patients with 
prior stable INRs who started dronedarone between July 2009 and May 2011 were 
identified. After dronedarone was added, subjects with unstable INRs were cases 
and those remaining stable INRs were controls. Data were retrospectively 
collected via charts review. Primary outcomes were pharmacist-judged unstable 
INR status and required warfarin dose adjustments to reach stable INRs again. 
Secondary outcomes were post-INRs and safety measures. Pre-post changes 
were assessed using paired t-tests. Exploratory logistic and linear regression 
models were used to identify predictors for primary outcomes. RESULTS: Of 131 
subjects, 44 (33.6%) were cases. A difference in baseline characteristics between 
groups was a target INR range not 2.0-3.0 (p=0.030), which remains a predictor of 
unstable INRs after adjustments for confounders (OR=7.95, 95% CI 1.58-40.09, 
p=0.012). Forty subjects (30.5%) had increased INRs >0.5, and two (1.5%) had ER 
visits. No dose adjustment was made in controls. Compared to pre-doses, post-
doses were significantly reduced in cases (-5.14 mg or -14.3%, p<0.001). Absolute 
dose changes were associated with pre-dose (p<0.001), INR target not 2.0-3.0 
(p=0.028) and degree of post-INRs deviated from the target (p<0.001). When the 
outcomes were dose changes in percentage, only the latter remained a predictor 
(p<0.001). CONCLUSIONS: After dronedarone was added, warfarin doses were 
downward adjusted in about one-third of patients. The potential drug-drug 
interaction between dronedarone and warfarin should be considered in clinical 
practice.  
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BUDGET IMPACTS OF POTENTIAL MODIFICATION OF RISK FACTORS FOR 
HEART FAILURE HOSPITALIZATIONS: A CONTEMPORARY MEDICAID COHORT 
ANALYSIS  
Shaya FT1, Breunig IM1, Mehra MR2 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Harvard Medical School, 
Boston, MA, USA  
OBJECTIVES: Increasing prevalence of heart failure (HF), increasing enrollment in 
state programs, and the economic burden of hospitalization among Medicaid 
patients necessitate an assessment of the budget impact of key risk factors for 
HF patients in a contemporary Medicaid population. METHODS: Claims from 
Maryland Medicaid, for 14,149 non-dual enrolled, 18-64 year olds with an HF 
diagnosis between July 1, 2005- December 31, 2009, follow-up >=six months. 
Weighted Cox Regression estimated average risk of any hospitalization 
attributable to various comorbidities and first-line therapy use, controlling for 
confounders. Noting the prevalence of comorbidity and therapy use, and mean 
cost of primary HF hospitalization for non-dual enrolled Maryland Medicaid 
patients in 2010 ($16,963 in 2011 dollars), numbers-needed-to-treat (NNT) were 
used to conservatively estimate the expected annual impact to the Maryland 
Medicaid budget attributable to 20% increases in prescribing rates (comorbidity 
prevalence) and associated reduction (increase) in hospitalization rates. 
RESULTS: Most patients were >45 years (71%), female (56%), and black (60%).  
Use prevalence was: beta-blockers (26%), ACE-inhibitors/ARB (29%), aldosterone 
antagonists (AA, 5%), and others including nitrates+hydralazine (37%). 
Comorbidity prevalence: hypertension (73%), psychological disorder (55%), 
chronic ischemic heart disease (CIHD, 43%), diabetes (41%), hyperlipidemia (37%), 
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chronic obstructive pulmonary disease (COPD, 27%), renal dysfunction (27%), 
stroke (21%), other cardiovascular disease (CVD, 78%). NNT to prevent  
one hospitalization annually (budget impact per HF patient in sample): 12 (-$89) 
ACE-inhibitor/ARB, 15 (-$60) beta-blockers, or 11 (-$123) other cardiovascular 
drugs; -27 ($92) hypertension, 11 (-$179) psychological disorder, -12 ($133) CIHD, -
12 ($118) diabetes, 13 (-$98) hyperlipidemia, -10 ($97) COPD, -8 ($116)  
renal dysfunction, -12 ($60) stroke, -8 ($322) CVD. CONCLUSIONS: Increasing 
enrollment in state Medicaid plans and other entitlement programs call for  
more deliberate, proactive and cost-effective disease and risk management  
of plan enrollees. Substantive savings to Medicaid can be achieved with  
small changes in the prevalence of common comorbid conditions or prescribing 
rates.  
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HOSPITAL BUDGET IMPACT OF READMISSION PENALTIES AND BUNDLED 
PAYMENTS: POTENTIAL IMPACT OF CORONARY STENT PLATFORMS  
Kansal AR1, Stern S1, Cohen D2, Reifsnider O1, Meskan T3, Allocco D3, Hale BC3 
1United BioSource Corporation, Bethesda, MD, USA, 2Saint Luke's Mid America Heart Institute, 
Kansas City, MO, USA, 3Boston Scientific, Natick, MA, USA  
OBJECTIVES: The Affordable Care Act established the Hospital Readmission 
Reduction Program (HRRP) and the Bundled Payments for Care Initiative (BPCI), 
which may reduce Medicare payments to hospitals. We assessed these 
programs’ impact on hospital budget, focusing on the potential to reduce 
penalties via improved short-term percutaneous coronary intervention (PCI) 
outcomes. METHODS: A budget impact model was developed to quantify the 
financial penalties associated with HRRP and the difference between fee-for-
service and bundled payments under BPCI for a hospital. HRRP penalties were 
associated with excess readmissions for patients admitted with acute 
myocardial infarction (AMI), pneumonia, and heart failure. The model also 
computed payment reductions under BPCI for all PCI patients regardless of 
diagnosis. An example hospital with high volume catheterization lab (1000 
PCIs/year; 50% Medicare) and total Medicare DRG-based payments of $110 
million/year was considered. The hospital was assumed to have excess 
readmission ratios at the seventy-fifth percentile for each condition. Based on 
recent clinical trials of stent platforms, we assumed an absolute 1% reduction in 
PCI-related readmission due to AMI and revascularization over 30 days following 
PCI. RESULTS: Total HRRP penalties for the example hospital were calculated to 
be $669,025, with $199,130 additional reduction in payments under BPCI.  
Our model projected that reducing readmission post-PCIs by 1% would  
reduce excess readmission ratio for patients with AMI from 1.052 to 1.037  
and thus HRRP penalties by $80,975. Total cost of care for the 500 Medicare 
patients receiving PCI was reduced by $43,791 due to reduction of subsequent 
clinical events, a savings accrued by hospitals under BPCI, resulting in net 
hospital savings of $124,766. Achieving these savings with newer stent platforms 
would result in effective hospital savings of $156/stent. CONCLUSIONS: A 1% 
reduction in PCI-related readmissions may substantially reduce penalties  
under HRRP and BPCI. Such reductions may be achievable using new stent 
platforms.  
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BUDGET IMPACT OF THROMBOLYSIS FOR MYOCARDIAL INFARCTION WITH 
SUPRA ST IN COLOMBIA  
Rosselli D1, Moreno A1, Rueda JD1, Herran S2 
1Pontificia Universidad Javeriana, Bogota, Colombia, 2Boehringer Ingelheim, Bogota, Bogota, 
Colombia  
OBJECTIVES: Despite national and international guideline recommendations, 
only a small proportion (estimated in 39%) of ST elevation myocardial infarctions 
(STEMI) that arrive in the 8-hour "therapeutic window" in Colombia receive 
thrombolytic treatment; our objective was to estimate the budget impact of a 
gradual implementation of this therapeutic approach. METHODS: In our excel 
based model we applied ISPOR's principles of good practice for budget impact 
analysis. The perspective was from the Colombian health system; we used a 5-
year time horizon (2012-2016). The model compared two different scenarios: 
continuing the current practice, with no increase in the proportion of 
thrombolized patients, while the other (Scenario 2) assumed a gradual increase 
(5 percentage points) of thrombolized patients, and an increase in tenecteplase 
use from (3 to 25% of all patients) along the five year period. RESULTS: Our 
estimated total cost of STEMI in Colombia for 2012, with 984 patients 
thrombolyzed nationwide, was US$728,291. With an increase in the use of 
thrombolysis (Scenario 2) the cost would increase by US$ 42,270 during the 
second year, US$87,596 during the third year, US$136,051 in the fourth year and 
US$187,716 in the fifth year (with a 15% overall increase in the number of 
thrombolyzed patients). This cost increase is due to an increase in the target 
population (estimated by official demographic projections), an increase in the 
proportion of patients with myocardial infarction receiving thrombolyisis and an 
increase in those receiving tenecteplase instead of streptokynase. 
CONCLUSIONS: Our country needs to allocate resources to prevent and treat 
cardiovascular diseases; applying current standards established in evidence-
based guidelines of myocardial infarction treatment should be an affordable 
investment.  
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COST OF PHARMACOTHERAPEUTIC MANAGEMENT OF HYPERTENSION IN A 
PRIVATE TEACHING HOSPITAL IN NIGERIA  
Ganiyu KA1, Suleiman IA2 
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OBJECTIVES: The study assessed economic burden of pharmacotherapy in 
hypertension management on the National Health insurance Scheme (NHIS) of 
Nigeria, Health Maintenance Organizations (HMOs), the individual patients, and 
the companies as well as the economies of antihypertensives selection. 
METHODS: Two hundred and fifty case notes of hypertensive patients attending 
out-patient-department of the hospital (between August 1st – November 30th, 
2011) were randomly selected. Selection criteria required that patients must  
be on at least an antihypertensive and first diagnosed after 2003. These  
were assessed for costs of pharmacotherapeutic management of hypertension  
as well as drug funding status.Requisite patients’ information extracted  
from case notes included: hospital number, age, gender, occupations, drugs, 
dosages and patients’ drug funding status. Drugs’ prices were obtained from  
the hospital billing guide. Data analysis was carried out using Microsoft  
excel and SPSS v16.0 for windows. RESULTS: Two hundred and eight of the 
selected case notes met the study criteria out of which 125 (60.1%) were males, 
while 83 (39.9%) were females. Most of the patients work for the government 98 
(47.1%). Others either work for private companies 51 (24.5%) or are self-employed 
25 (12%). Retirees constituted 11.5% of the lot while 4.8% were unemployed. 
Diuretics were the most economical at an average monthly cost per prescription 
of  858.6 ($5.51) and was closely followed by the beta-blockers at  1,101.1 ($7.07). 
The total estimated monthly cost of the antihypertensives prescribed in the 
study was  892,650 ($5730.93). HMOs having 104 (50.0%) of the cohort as enrollees 
incurred most of the cost at  446,325.0 ($2865.47). NHIS and Companies with 75 
(36.0%) and 17 (8.2%) of the enrollees respectively incurred  321,354.0 ($2,063.14) 
and  73,197.3 ($469.94). Private patients 12 (5.8%) incurred the least at  51,773.7 
($332.39). CONCLUSIONS: HMOs and NHIS incurred most of the cost of 
antihypertensives prescribed and diuretics were the most economical of all.  
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EVALUATION THE FEASIBILITY OF SOME SCHEMES OF ANTIHYPERTENSIVE 
THERAPY ON THE BUDGET IMPACT ANALYSIS AND MISSED OPPORTUNITIES 
ANALYSIS IN UKRAINE  
Iakovlieva L1, Mishchenko O1, Gerasymovà O1, Bezditko N2, Kyrychenko O3,  
Tkachovà O1 
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Ukraine, 
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OBJECTIVES: Pharmacoeconomic analysis of two schemes antihypertensive 
therapy: diroton (lisinopril) (tab. 10 mg 128, Gedeon Richter) compared with lipryl 
(tab. 10 mg 130, BHFZ) and two regimens with fixed combinations of ACE 
(captopril) + diuretic (hypothiazide): kapozyd (tab. 50mh/25mh 130, BMS) 
compared with captopres-D (tab. 50mh/25mh 120, Darnitsa) for one year in 
Ukraine. METHODS: Cost minimization analysis, budget impact analysis and 
analysis of missed opportunities were used. RESULTS: In condition of equal 
efficacy lipryl is less expensive (costs of treatment per patient for year - 292 UAH) 
compared with diroton (costs of treatment per patient for year - 620.50 UAH). 
Indicator of missed opportunities in the transition to less expensive drug is 
1.125. According to official statistics of Ministry of Health in Ukraine there are 
12.1 millions patients with hypertension, or 32.2% of the adult population. The 
costs of lipryl treating this population are 3540 millions UAH, for diroton - 7522 
millions UAH. The transition to lipryl economy of budgetary funds will be 3982 
millions UAH. The analysis of two schemes of antihypertensive therapy with 
fixed combinations of ACE inhibitors (captopril) + diuretic (hypothiazide) shows 
that in condition of equal efficacy captopres-D is less expensive (costs of 
treatment per patient for year - 295.65 UAH) compared with kapozyd (costs of 
treatment per patient for year – 511 UAH). Indicator of missed opportunities is 
0.728. Given the number of patients with hypertension, the costs of captopres- 
D treating this population will be 3584 millions UAH, for kapozyd - 6194.6 
millions UAH. In condition of budget financing in the transition to captopres-D 
economy of budgetary funds will be 2610.6 millions UAH. CONCLUSIONS: The 
results of the analysis prove the economic feasibility of domestic 
antihypertensive drugs.  
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ECONOMIC IMPACT OF SWITCHING TO FIXED-DOSE COMBINATION THERAPY 
FOR JAPANESE HYPERTENSIVE PATIENTS: A RETROSPECTIVE COST ANALYSIS  
Akazawa M1, Fukuoka K2 
1Meiji Pharmaceutical University, Tokyo, Japan, 2Nihon Chouzai Co., Ltd., Tokyo, Japan  
OBJECTIVES: The prescription of fixed-dose combinations (FDC) of 
antihypertensive drugs has increased rapidly since the relaxation of the 
prescription-term restriction. In this study, we used the opportunity of this 
policy change in Japan to examine the economic benefits of switching to FDC. 
METHODS: Claims data from 64 community pharmacies located in Tokyo were 
used to identify hypertensive patients under continuous treatment with 
angiotensin-receptor blockers (ARBs). Patients switching to FDC between 
December 2010 and April 2011 were compared to patients who did not receive 
FDC (control group). Changes in annual total and antihypertensive drug costs 
were compared for both groups, using a difference-in-differences approach to 
adjust for patient characteristics and use of concomitant medication. RESULTS: 
There were 542 patients who switched to FDC and 9664 patients in the control 
group. No significant differences were observed between the 2 groups, except for 
antihypertensive drug use patterns before the policy change. The switch to FDC 
was associated with annual savings of 6151 yen (US$87.70) in total drug costs 
and 10,420 yen (US$124.20) in antihypertensive drug costs. Approximately 20% of 
the FDC patients, however, switched from ARB alone and their treatment costs 
increased by 3795 yen (US$37.10). CONCLUSIONS: For hypertensive patients who 
required ARB-based combination therapy, switching to FDC drugs had a 
significant cost-saving effect. However, the policy change of relaxing the 
prescription-term restriction could encourage aggressive treatment, i.e., 
